BNP Paribas Financial Markets
MPLT

BNP Paribas Financial Markets’s MapLight Therapeutics MPLT Stock Holding History

BNP Paribas Financial Markets’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Buy
70,484
+33,183
+89% +$954K ﹤0.01% 2628
2026
Q1 		$758K Buy
37,301
+33,846
+980% +$605K ﹤0.01% 3331
2025
Q4 		$60.7K Buy
+3,455
New +$57.9K ﹤0.01% 4592

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BNP Paribas Financial Markets's MPLT Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its MapLight Therapeutics (MPLT) stake by 89% in Q2 2026, buying an estimated $954K and bringing the position to 70,484 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2628.

BNP Paribas Financial Markets first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • BNP Paribas Financial Markets held 70,484 shares of MapLight Therapeutics worth $2.53M as of Q2 2026.
  • BNP Paribas Financial Markets bought 33,183 MapLight Therapeutics shares in Q2 2026, an estimated $954K.
  • MapLight Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2628 holding.
  • BNP Paribas Financial Markets first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.